1. Annual report 2024
  2. Research
  3. GREMPAL

GREMPAL

Primary Care Research Group in Common Disorders of the Musculoskeletal System

The Research Group on Prevalent Diseases of the Musculoskeletal System in Primary Care (GREMPAL-consolidated group since 2017) is currently directed by Daniel Martínez Laguna and is made up of Carlen Reyes Reyes, Meritxell Aivar Blanch, Cristina Carbonell Abella, Maria Antonia Pou and César Diaz Torné.

His established lines of research are the epidemiology of osteoporosis and osteoarthritis, fragility fractures and the pharmaco-epidemiology of the most widely used treatments. In addition, she has incorporated new lines of research: gout (Maria Antonia Pou) and rheumatoid arthritis (César Diaz Torné). GREMPAL has continued with national and international collaborations; since 2021, with the Real-World Epidemiology group (IDIAP Jordi gol) through the joint hiring of Carlen Reyes as a postdoctoral researcher.

Since 2023, with the University of Oxford with international study ? Epidemiology and Burden of Imminent Subsequent Fractures in postmenopausal women? and in the future with the Medicines Unit through a grant to the health research funds of the Carlos III Institute related to vitamin D. César Diaz Torné will open the door to future collaborations with the Rheumatology Unit of the Hospital de Sant Pau and together with Maria Antònia Pou they will create links with the Department of Rheumatology of the University of Auckland (New Zealand) where they will spend a few months.

Group projects

  • Prognostic models of morbidity and mortality of stable and decompensated heart failure in Primary Care. (PREDOC_ECO-23/8). ICS - Catalan Institute of Health. 2024-2029. PI: Maria Antònia Pou Giménez,Victoria Cendrós Cámara.
  • Improvement in the management of gout in primary care. Department of General Practice and Primary Health Care, University of Auckland. New Zealand. (EST-22/2). Jordi Gol i Gurina Primary Care Research Institute (IDIAPJGol). 2023-2024. PI: Maria Antònia Pou Giménez.
  • Improvement of gout management in primary care. Department of General Practice and Primary Health Care, University of Auckland. New Zealand. (COM_EST-22/1). Jordi Gol i Gurina Primary Care Research Institute (IDIAPJGol). 2023-2024. PI: Maria Antònia Pou Giménez.
  • Qualitative study on the impact of gout on parenting. 2024-2027. PI: Maria Antònia Pou Giménez.
  • Treatment of gout in primary care in Catalonia. 2024-2027. PI: Maria Antònia Pou Giménez.
  • Knowledge of gouty arthropathy of Family and Community Medicine residents in Catalonia. ICS - Catalan Institute of Health. 2023-2024. PI: Maria Antònia Pou Giménez.
  • WHAT IS THE IMPACT OF GOUT ON EMPLOYMENT? A QUALITATIVE STUDY THROUGH INTERVIEWS WITH PEOPLE WITH GOUT. 2023-2026. PI: Maria Antònia Pou Giménez.
  • Epidemiology and burden of imminent subsequent fractures in postmenopausal women. University of Oxford. 2023-2026. IP: Carlen Reyes Reyes.
  • Effects of Angiotensin-converting enzyme Inhibitors and Angiotensin receptor blockers: protocol for a Spanish cohort study using routinely collected electronic health records with validation against the ONTARGET trial. London School of Hygiene & Tropical Medicine. 2022-2025. IP: Carlen Reyes Reyes.
  • Utilization and safety of antidementia treatments: a large longitudinal population-based study in Catalonia. Jordi Gol i Gurina Primary Care Research Institute (IDIAPJGol). 2022-2025. PI: Carlen Reyes Reyes.
  • Validation of the diagnosis of gout in the database of the computerized medical history of Primary Care. ICS - Catalan Institute of Health. 2022-2025. PI: Maria Antònia Pou Giménez.
  • European Non-interventional Post Authorization Safety Study for romosozumab by the EU-ADR Alliance. 2018-2026. IP: Carlen Reyes Reyes.
  • Efficacy of osteoporosis drugs in patients with type 2 diabetes mellitus: a population-based cohort study. Spanish Foundation for Bone Research and Mineral Metabolism (FEIOMM). 2018-2025. PI: Daniel Martínez Laguna.
  • Gout and Parkinson's disease in an urban Mediterranean population: a case-control study. PI: Maria Antònia Pou Giménez.
  • Incidence and association between exposure to potentially inappropriate medications of the STOPPFall tool and the risk of adverse events: a population-based cohort study. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2024-2027. PI: Carlen Reyes Reyes.
  • Association between vitamin D levels in the blood, vitamin D supplementation and osteoporotic fractures in the Catalan population: a population-based study. 2024-2027. PI: Carlen Reyes Reyes.

Group publications

  • Khera R, Aminorroaya A, Dhingra LS, Thangaraj PM, Pedroso Camargos A, Bu F et al. Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes: A Multinational, Federated Analysis of LEGEND-T2DM. J. Am. Coll. Cardiol. 2024; 84(10):904-917. PMID:39197980.
  • Diaz Torne C, Pou MA, Horne A, Gasteiger C, Dalbeth N. 'Gout was like the boss'. A qualitative study exploring the impact of gout on employment. RMD Open. 2024; 10(3):1-8. PMID:39160089.
  • Pou MA, Martinez Laguna D, Diaz Torne C. Gout, beyond the joint: How should we treat it?. Semergen. 2024; 50(5):102176-102176. PMID:38301402.
  • Martínez Laguna D, Carbonell Abella C, Bastida JC, González M, Micó Pérez RM, Vargas F et al. Secondary fracture prevention in Spanish primary care: results of the PREFRAOS Study. Arch. Osteoporosis. 2024; 19(1):35-35. PMID:38722400.
  • Mercadé Besora N, Li X, Kolde R, Trinh NT, Sanchez Santos MT, Man WY et al. The role of COVID-19 vaccines in preventing post-COVID-19 thromboembolic and cardiovascular complications. Heart. 2024; 110(9):635-643. PMID:38471729.
  • Reyes C, Newby D, Raventós B, Verhamme K, Mosseveld M, Prieto Alhambra D et al. Trends of use and characterisation of anti-dementia drugs users: a large multinational-network population-based study. Age Ageing. 2024; 53(5):PMID:38783756.
  • Bover J, Gómez Alonso C, Casado E, Rodríguez García M, Lloret MJ, Castro Alonso C et al. Osteoporosis management in patients with chronic kidney disease (ERCOS Study): A challenge in nephrological care. Nefrologia. 2024; 44(2):241-250. PMID:38531765.
  • Markus AF, Rijnbeek PR, Kors JA, Burn E, Duarte Salles T, Haug M et al. Real-world treatment trajectories of adults with newly diagnosed asthma or COPD. BMJ Open Respir Res. 2024; 11(1): PMID:38413124.
  • Fabiano G, Chen XH, Rathod Mistry T, Delmestri A, Njuki LN, Moayyeri A et al. Feasibility of a Federated Network Analysis Using Real-World Data Mapped to OMOP Common Data Model to Estimate Healthcare Resource Utilisation and Costs of Imminent Subsequent Fracture. Pharmacoepidemiol Drug Saf. 2024;33391-391.
  • Raventós B, Chen XH, Stanford T, Prieto Alhambra D, Porce LM, Reyes C et al. Prescription Sequence Symmetry Analysis to Identify Prescription Cascades for Dementia Drug Treatments in the United Kingdom. Pharmacoepidemiol Drug Saf. 2024;33399-400.
  • Chen X, Rathod Mistry T, Fabiano G, Moayyeri A, Warden J, Reyes C et al. Subsequent fractures in postmenopausal women with fragility fractures: incidence and patient characteristics from six european countries. Aging Clin. Exp. Res. 2024;36605-605.
Anar a l'inici